Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced on October 29, 2026, that it is expanding its multi-centre comparative clinical studies evaluating its blood-based TELO-MRD assay against Adaptive Biotechnologies' clonoSEQ® next-generation sequencing platform for measurable residual disease assessment in multiple myeloma. The initiative adds cohorts from Greece, Canada, and the United States to supplement a planned French study, broadening the statistical base supporting the company's validation programme. With commercialisation targeted for the end of calendar 2027, investors may be watching the progress of these parallel studies closely.

Key Points

  • Telo Genomics Corp. (TSXV: TELO / OTCQB: TDSGF) is a Vancouver-based biotech developing telomere-based diagnostic tests.
  • The company is expanding comparative clinical validation of its TELO-MRD assay against clonoSEQ® across multiple independent patient cohorts in four countries.
  • Comparative testing on the French IFM 2018-04 cohort is scheduled to commence in Q4 2026; new cohorts include approximately 25–30 samples from Athens, 10 monitoring time points from Montreal's Jewish General Hospital, and U.S. patients from Cleveland Clinic.
  • TELO-MRD is not yet commercially available; the company targets a commercial application by end of calendar 2027.

How TELO-MRD Differs From Bone-Marrow Standard-of-Care Testing

TELO-MRD is a liquid-biopsy approach combining enumeration of circulating myeloma plasma cells with three-dimensional telomere profiling using the company's proprietary TeloView® platform. The assay is designed to detect residual disease from peripheral blood rather than a bone-marrow biopsy, which the release states is often limited by the patchy distribution of disease. Standard MRD methods, including clonoSEQ®, rely on bone-marrow sampling and, in the case of clonotype-dependent sequencing, require identification of a dominant clone — a potential constraint the blood-based approach seeks to address.

Four-Country Cohort Strategy Supporting the Validation Programme

The company's multi-centre strategy is anchored by the IFM 2018-04 study at the University of Nantes, France, where Adaptive clonoSEQ® results have already been collected and comparative TELO-MRD testing is scheduled to begin in Q4 2026. In parallel, Telo Genomics is obtaining approximately 25–30 samples with available clonoSEQ® data from the University of Athens, expanding comparative data from its ongoing collaboration at Jewish General Hospital in Montreal, and actively recruiting patients at Cleveland Clinic in the United States in collaboration with Dr. Sandra Mazzoni. The company states these parallel initiatives are intended to accelerate the generation of comparative clinical evidence.

CEO Commercialisation Commentary and Development Status

Chief Executive Officer and Chairman John Farlinger stated that the multi-centre initiatives reflect the company's commitment to building a robust comparative dataset and that expanding beyond a single cohort will allow performance evaluation across independent patient populations. The release confirms TELO-MRD is not yet commercially available and that the company's objective is a commercial application by the end of calendar 2027. The disclosure also cautions that these studies are research comparisons, are not a basis for treatment decisions, and that results will require confirmation in larger, independent studies.